Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
144.1 EUR | +0.02% |
|
+1.27% | +17.89% |
07-15 | Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast... | ![]() |
07-15 | AstraZeneca: acquisition of Amolyt Pharma finalized | CF |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.89% | 244B | - | ||
+62.78% | 856B | C+ | ||
+39.19% | 631B | B | ||
-3.87% | 359B | C+ | ||
+17.86% | 325B | B- | ||
+9.00% | 297B | C+ | ||
+5.81% | 234B | A+ | ||
+16.73% | 226B | B- | ||
+16.31% | 177B | C+ | ||
+1.84% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- ZEG Stock
- Ratings AstraZeneca PLC